Schrodinger, INC

Schrodinger, Inc. announced it received approximately $57 million in cash following the completion of Eli Lilly and Company's acquisition of Ajax Therapeutics, Inc., a company co-founded by Schrodinger.

Schrodinger, Inc. has formalized the separation of its Chief Commercial Officer, Mannix Aklian, outlining terms for continued benefits and payments.

Schrodinger, Inc. reported the departure of its Chief Commercial Officer and reaffirmed its financial and operational guidance for the second quarter and full year 2026.

Schrodinger, Inc. announced the appointment of Therese Abrams as its new Principal Accounting Officer, succeeding Jenny Herman who will depart after a transition period.

Schrdinger, Inc. announced robust full-year 2025 financial results, including 23% total revenue growth and a reduced net loss, alongside a strategic shift to hosted software and a path to positive adjusted EBITDA by 2028.

Schrodinger reported robust third-quarter 2025 financial results with significant revenue growth, reduced net loss, and a strategic shift in its therapeutics R&D model.

Schrodinger, Inc. reported a 54% revenue increase to $54.3 million in Q3 2025 and a narrowed net loss, driven by strong drug discovery and software growth, despite discontinuing a key clinical program.

Schrodinger, Inc. reported a 16% increase in total revenues for Q2 2025, narrowing its net loss and achieving positive operating cash flow, driven by strong software growth and a significant upfront payment from a new drug discovery collaboration.

Schrdinger, Inc. announces a 63% increase in total revenue for Q1 2025, fueled by growth in both its software and drug discovery segments.

Schrödinger Inc. experienced a revenue decrease in Q3 2024, primarily due to a decline in drug discovery revenue, while software revenue showed modest growth.

Schrdinger, Inc. announced its second quarter 2024 financial results, highlighting a 35% increase in total revenue compared to the same period last year.

Schrodinger Inc. experienced a significant decrease in revenue during the first quarter of 2024, primarily due to a decline in drug discovery revenue, while software revenue saw a modest increase.

Schrodinger, Inc. reported a 23% increase in total revenue to $255.9 million and significantly reduced its net loss to $103.3 million in 2025, driven by robust software sales and drug discovery collaborations, despite discontinuing a key clinical program.

Schrodinger, Inc. reports its full year 2024 financial results, showcasing growth in software revenue and advancements in its collaborative and proprietary drug discovery programs.

Schrdinger, Inc. announces its full year 2023 financial results, showcasing a 20% increase in total revenue and a net income of $40.7 million.

Rachit Jain, EVP & CFO of Schrodinger, Inc., sold 875 shares of common stock on July 16, 2026 for $15.60 per share.

Richard Friesner, a Director at Schrodinger, Inc., reported transactions involving the transfer of common stock from a grantor retained annuity trust to a family trust and direct ownership.

Schrodinger, Inc. President and CEO Ramy Farid exercised stock options and sold shares under a pre-established 10b5-1 plan.

EVP & CFO Rachit Jain sold 844 shares of Schrodinger, Inc. to cover tax withholding obligations related to RSU vesting.

Schrodinger's Chief Accounting Officer, Jenny Herman, sold common stock to cover tax liabilities from RSU vesting, not as a discretionary trade.

Schrodinger's EVP & CFO, Rachit Jain, reported a planned sale of 1,631 common shares to cover tax liabilities from RSU vesting, executed under a Rule 10b5-1 plan.

Schrodinger, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 22, 2026, to vote on director elections, executive compensation, and equity plan amendments.

Schrödinger, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Schrödinger, Inc. will hold its 2025 annual meeting of stockholders virtually on June 18, 2025, to vote on director elections, executive compensation, and auditor ratification.

Schrödinger Inc. has updated its proxy statement to reflect changes in director nominee Ramy Farid's biographical information, specifically regarding his board memberships at other public companies.

Schrödinger, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

Schrdinger is asking stockholders to approve amendments to its equity incentive and employee stock purchase plans, as well as its certificate of incorporation to reflect new Delaware law provisions regarding officer exculpation, at the upcoming annual meeting.

Sumitomo Mitsui Trust Group, Inc. and Amova Asset Management Co., Ltd. have reported a 4.9% beneficial ownership in Schrodinger, Inc. common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 6.04% in Schrodinger Inc. common stock as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Schrodinger Inc. following an internal realignment on January 12, 2026.

Rubric Capital Management LP and David Rosen have reported an increased beneficial ownership of 6.47% in Schrodinger, Inc., holding 4,171,498 shares as of December 31, 2025.

Sumitomo Mitsui Trust Group and Amova Asset Management Co., Ltd. reported a 7.1% passive beneficial ownership in Schrodinger, Inc. common stock.

BlackRock, Inc. has disclosed an increased beneficial ownership of 12.7% in Schrodinger, Inc., holding over 8.1 million shares as of a future event date.